
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Bicara Therapeutics Inc. Common Stock (BCAX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BCAX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $32.6
1 Year Target Price $32.6
4 | Strong Buy |
2 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.41% | Avg. Invested days 13 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 622.56M USD | Price to earnings Ratio - | 1Y Target Price 32.6 |
Price to earnings Ratio - | 1Y Target Price 32.6 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 7.80 - 28.09 | Updated Date 08/15/2025 |
52 Weeks Range 7.80 - 28.09 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.66 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.5367 | Actual -0.5 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.85% | Return on Equity (TTM) -32.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 188194015 | Price to Sales(TTM) - |
Enterprise Value 188194015 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 54562800 | Shares Floating 26351124 |
Shares Outstanding 54562800 | Shares Floating 26351124 | ||
Percent Insiders 12.23 | Percent Institutions 99.84 |
Upturn AI SWOT
Bicara Therapeutics Inc. Common Stock
Company Overview
History and Background
Bicara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing dual-action biologics that combine the precision of antibodies with the power of TLR agonists to drive potent and durable anti-tumor responses. Founded in 2018, they're advancing a pipeline of novel therapies designed to address unmet needs in cancer treatment.
Core Business Areas
- Oncology Therapeutics Development: Developing and commercializing novel dual-action biologics for cancer treatment.
- Antibody Engineering: Engineering novel antibodies with enhanced specificity and efficacy.
- TLR Agonist Technology: Utilizing TLR agonists to stimulate the immune system to fight cancer.
Leadership and Structure
The leadership team includes experienced professionals in drug development, clinical trials, and business development. The company's structure is typical of a biotech firm, with departments focused on research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- BCA101: A bifunctional antibody targeting EGFR and engaging TLR9, currently in clinical trials for advanced solid tumors. Market share data is not yet available due to its clinical stage. Competitors include companies developing EGFR inhibitors and TLR9 agonists.
- Pipeline Programs: Other preclinical programs targeting various cancer pathways. Market share data is not available for preclinical programs. Competitors include companies developing similar therapeutics for specific cancer indications.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and growing, driven by an increasing incidence of cancer and advancements in treatment options. Immunotherapy and targeted therapies are major areas of innovation.
Positioning
Bicara Therapeutics is positioned as an innovator in the field of dual-action biologics for cancer. Their competitive advantage lies in their proprietary technology platform that combines antibody specificity with TLR agonist stimulation.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be hundreds of billions of dollars. Bicara is positioned to capture a portion of this market by developing differentiated therapies that address unmet needs.
Upturn SWOT Analysis
Strengths
- Novel technology platform
- Experienced management team
- Promising preclinical and clinical data
- Strong intellectual property position
Weaknesses
- Early-stage company
- Limited financial resources
- High risk of clinical trial failure
- Dependence on key personnel
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Positive clinical trial results
- Market demand for innovative cancer therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in reimbursement policies
- Unexpected adverse events in clinical trials
Competitors and Market Share
Key Competitors
- MRTX
- LLY
- REGN
Competitive Landscape
Bicara's dual-action approach offers a potential advantage over single-target therapies. However, it faces competition from larger companies with more resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data not available, as it's an early-stage company.
Future Projections: Future growth is dependent on clinical trial success and potential partnerships. Analyst estimates are not available.
Recent Initiatives: Focusing on advancing BCA101 through clinical trials and expanding pipeline with new dual-action biologics.
Summary
Bicara Therapeutics is a clinical-stage biopharmaceutical company with a novel dual-action biologic platform that shows promise in oncology. The company's technology and management team are key strengths. The main challenges are clinical trial success and competition. Securing partnerships is vital to its growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Bicara Therapeutics' Website
- SEC Filings
- Industry Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bicara Therapeutics Inc. Common Stock
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-09-13 | CEO & Director Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://www.bicara.com |
Full time employees 55 | Website https://www.bicara.com |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.